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cocci are more common. 3) Embolisms in other locations are more frequent. 4) Septic
shock is more frequent. 5) Death and the need for valve surgery are not influenced by the
existence of these embolisms. 
1143-140 Reoperative Valve Replacement With the St. Jude 
Medical Valve Prosthesis: Long-Term Follow-Up
Robert W. Emery, Kit V. Arom, Christopher Krogh, Lyle D. Joyce, Demetre Nicoloff, 
Minnesota Cardiovascular & Thoracic Surgeons, LLC, St. Paul, MN
OBJECTIVE: From 6/78 – 9/02, 451 redo open heart patients (following various primary
cardiac operations) age range 18-91 years (average age 62 ± 14) underwent single-valve
replacement with the St. Jude Medical (SJM) heart valve. Of 248 patients having aortic
(AVR) and 203 patients having mitral valve replacements (MVR), 35% and 21% had con-
comitant coronary bypass respectively.
METHODS: Cardiac Surgical Associates has maintained an independent database of
our patients with the SJM prosthesis since the world’s first implant in 10/77. Patients were
contacted by questionnaire and/or phone from 11/02 through 6/03. Hospital course and
valve-related events were verified by patient chart review and/or physician contact.
RESULTS: Follow-up was 95% complete for a total of 3,115 patient years (1,671 AVR;
1,443 MVR). Follow-up ranged from 0.1 to 24.3 years (average 7 ± 6 years). Operative
mortality was 9% (10% AVR, 8% MVR). Five deaths (13%) were valve related. Freedom
from all late mortality at 24 years was 64% (70% AVR, 56% MVR), and from valve-related
mortality 83% (84% AVR, 82% MVR). Freedom from thromboembolic events was 85%
(91% AVR, 82% MVR), from bleeding events 83% (83%AVR, 82% MVR), from
endocarditis 97% (97% AVR, 97% MVR), from valve thrombosis 98% (99% AVR, 98%
MVR), and from subsequent reoperation 94% (95% AVR, 94% MVR),. There were no
structural failures.
CONCLUSION: Reoperative valve replacement carries a significant operative mortality,
but long term results with the SJM valve show a low event rate, a durable prosthetic valve
and excellent long-term patient survival.
ORAL CONTRIBUTIONS
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2:00 p.m.
851-1 Ischemic Mitral Regurgitation Does Not Influence 
Postinfarction Ventricular Remodeling
Sina L. Moainie, Yoshiharu Enomoto, Joseph H. Gorman, III, Benjamin M. Jackson, 
Theodore Plappert, Martin G. St. John-Sutton, Ahmad Zeeshan, Robert C. Gorman, 
University of Pennsylvania, Philadelphia, PA
Background: Despite sparse clinical data, surgical treatment for ischemic mitral regurgi-
tation (IMR) has become more aggressive. We used four well-developed ovine models of
postinfarction left ventricular (LV) remodeling to test the hypothesis that IMR does not sig-
nificantly contribute to postinfarction LV remodeling.
Methods: Infarction of 21% to 24% of the LV was induced by coronary ligation in 71
sheep. Infarctions varied only by anatomic location: anteroapical (AA), n=26; anterobasal
(AB), n=16; laterobasal (LB), n=9 and posterobasal (PB) n= 20. End systolic volume
(ESV), end diastolic volume, end systolic muscle to cavity area ratio (ESMCAR), ejection
fraction (EF) and degree of IMR as determined by quantitative echocardiography were
assessed before infarction and at 2, 5 and 8 weeks after infarction to evaluate the extent
of LV remodeling.
Results: All infarcts resulted in significant postinfarction remodeling and decreased EF
(table). AA infarcts led to LV aneurysms and resulted in more severe remodeling than the
three other infarct locations. Only PB infarcts caused severe and progressive IMR.
Remodeling due to PB infarcts was not more severe than that caused by infarcts at other
locations.
Conclusion: The extent of postinfarction remodeling is determined by infarct size and
location. The development of IMR does not contribute to adverse remodeling. IMR is a
manifestation rather than a cause of postinfarction remodeling. The current aggressive
surgical approach to IMR should be reassessed. 
2:15 p.m.
851-2 Reduction in Functional Mitral Regurgitation Using the 
Coapsys Annuloplasty Device in Patients Undergoing 
Off-Pump Coronary Artery Bypass Grafting: A 
Quantitative Echo Analysis
Sanjay Mittal, Yugal Mishra, Yatin Mehta, Naresh Trehan, Escorts Heart Institute and 
Research Centre, New Delhi, India
Background: We are evaluating a novel implantable device (Myocor® Coapsys™ Annu-
loplasty System) intended to treat functional mitral regurgitation (MR) on a beating heart
as conventional surgical correction increases mortality and morbidity over CABG alone.
Changes in mitral valve (MV) geometry induced by the device were evaluated using echo
techniques.
Methods: The Coapsys device was surgically implanted in 20 patients (mean age 58.7 ±
8.1 years, 3 females, mean ejection fraction 37.3 ± 6.2 %) with sustained MR grade 2 or
more after undergoing concomitant CABG. Patients with structural abnormalities of the
MV or its apparatus were excluded . Coapsys consists of anterior and posterior epicardial
pads connected by a flexible sub-valvular chord. The device is tightened under echo
guidance to minimize MR. Echo parameters (MR Grade; Maximum MR jet area; end-
diastolic antero-posterior (A-P) annular dimension and MV tenting area) were studied
pre-operatively and post-operatively (prior to discharge and 3 months).
Results: Implants were performed off-pump without device related adverse events. Echo
parameters were as Table 1. [* p<0.005 compared to pre-implantation]
Table 1 
Conclusions: The Coapsys device can be safely implanted on the beating heart.
Implantation of the device results in significant reductions in MR. MR jet area, A-P dimen-
sion, and MV tenting area are also significantly reduced. These functional and geometric
changes are maintained at 3-months.
2:30 p.m.
851-3 Staged Initial Percutaneous Coronary Intervention 
Followed by Valve Surgery (“Hybrid” Approach) for 
Patients With Complex Coronary and Valve Disease
John G. Byrne, Marzia Leacche, Tomislav Mihaljevic, Sary F. Aranki, James D. Rawn, 
Lawrence H. Cohn, Brigham and Women's Hospital, Boston, MA
Background:With advancements in percutaneous coronary interventions (PCI), some
patients requiring coronary revascularization and valve surgery may be better served
with a “hybrid” approach involving initial planned PCI followed by valve surgery in a
staged fashion rather than conventional high-risk valve/CABG. This may be particularly
relevant in hemodynamically unstable patients after acute coronary syndromes, and
some patients requiring valve reoperations.
Methods: We retrospectively analyzed 26 consecutive patients with coronary artery and
valve disease who were treated with planned initial PCI followed by valve surgery during
the same hospitalization between September 1997 and August 2003.
Results: Median age was 72.5 years (range 53-91 years), with 12M/14F. Mean NYHA
was 3.5±0.6. Acute myocardial infarction was present in 10/26 (38%) with cardiogenic
shock in 4/26 (15%) and low cardiac output syndrome in 6/26 (23%). 7/26 (27%) required
preoperative intubation. Balloon angioplasty was performed in every patient (n=26), fol-
Group I
Hepatosplenic or Renal 
Embolisms
n= 33
(%)
Group II
n= 305
(%)
P value
Prosthetic endocarditis 30.3 36.7 0.46
Embolisms in other locations 48.5 13.4 <0.001
Stroke at admission 33.3 15.1 0.008
Splenomegaly 24.2 10.9 0.04
S. aureus 30.3 16.1 0.04
Enterococci 18.2 8.2 0.05
Vegetations detected by TEE 97.0 78.0 0.01
Vegetation Size _10 mm 90.0 70.8 0.02
Septic shock 27.3 9.5 0.002
Persistent infection 54.5 32.8 0.01
Surgery 54.5 53.1 0.87
Mortality 39.4 30.8 0.31
Infarct Location IMR at 8 weeks
(0=no MR, 
4=severe MR)
ESV at 8 
weeks as % of 
preinfarction
ESMCAR at 
8weeks as % of 
preinfarction
EF at 8 weeks 
as % of 
preinfarction
Anteroapical(AA) 
n=26
0.7± 0.2 238±11* 86± 4 76± 34
Anterobasal(AB) 
n=16
0.5± 0.2 203±17 75±6 75± 38
Laterobasal(LB)
n=9
0.2± 0.2 191±19 83± 8 74± 23
Posterobasal(PB) 
n=20
2.8± 0.2** 218±12 74± 7 73± 21
* ESV significantly greater for AA infarcts than all other infarct locations at 8 wks
** IMR significantly greater for PB infarcts than all other infarct locations at 8 wks
Pre-implant Discharge Three Month
MR Grade 3.0±0.6 1.1±1.0* 1.3±0.8*
MR jet area (cm²) 7.9±3.7 3.5±2.0* 3.6±1.6*
Annular A-P Dimension 2.8±0.4 2.4±0.4* 2.6±0.4*
Mitral Tenting Area 3.9±1.0 2.8±1.0* 2.9±0.9*
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lowed by stenting in 22/26 (85%). Within median 5 days (range 0-14), 11/26 (42%) under-
went reoperative mitral (n=8) or aortic (n=3) valve surgery. The remaining 15 patients
underwent primary mitral (n=13), aortic (n=1) or double (n=1) valve surgery. Concomitant
CABG was performed to non-stented (non culprit) vessels in 9 primary mitral and 1 aortic
valve patients. Operative mortality was 3.8% (1/26). Survival at 1, 3 and 5 years was
78%, 56% and 44% respectively.
Conclusion: “Hybrid” initial PCI followed by staged valve surgery may represent an alter-
native to conventional valve/CABG in some high-risk patients, particularly those who
present in shock after myocardial infarction and some patients who require reoperative
valve surgery.
2:45 p.m.
851-4 Changing Outlook After Aortic Valve Surgery for 
Chronic Aortic Regurgitation With Severe Left 
Ventricular Dysfunction
Sunil K. Bhudia, Patrick M. McCarthy, Ganesh S. Kumpati, Katherine J. Hoercher, 
Jeevanantham Rajeswaran, Eugene H. Blackstone, The Cleveland Clinic Foundation, 
Cleveland, OH
Background: Historically, patients (pts) with chronic aortic regurgitation (AR) and severe
left ventricular (LV) dysfunction have been considered for transplant due to perceived
high operative mortality after aortic valve (AV) surgery and limited late survival. We
sought to determine change in hospital mortality over time, late survival compared with
pts without severe LV dysfunction, and risk factors for death after AV surgery.
Methods: From 1972 to 1999, 724 pts underwent AV surgery for chronic (>3 mo) AR; 88
(12%) had severe LV dysfunction (ejection fraction <30%). They were propensity
matched to pts with non-severe LV dysfunction to compare hospital mortality and time-
related survival. Propensity score adjusted multivariable analysis of all 724 pts was per-
formed to identify risk factors for death.
Results: Hospital mortality in pts with severe LV dysfunction has fallen to 0% (0/35) since
1985, comparable to that of propensity-matched pts with non-severe LV dysfunction
(Fig). Time-related survival in pts operated on from 1985 to 1999 was similar in both
groups (P=.96) and comparable to that of transplantation. Risk factors for death included
earlier date of surgery and severe LV dysfunction, but not interaction between them
(P=.5).
Conclusions: AV surgery in pts with severe LV dysfunction is no longer a futile, high-risk
procedure for which transplantation is the only option. Neutralization of severe LV dys-
function has been accomplished by across-the-board improvement in early results of AV
surgery. 
3:00 p.m.
851-5 Hemodynamic Response to Inhaled Nitric Oxide in 
Adult Cardiac Surgery
Frank D. Wagner, Tom Gromann, Deutsches Herzzentrum Berlin, Berlin, Germany
Background: Inhaled nitric oxide (iNO) has been established as a selective pulmonary
vasodilator in the treatment of pulmonary hypertension associated with acute right ven-
tricular (RV) failure. This study reviews our single-center experience with the use of iNO
in adult cardiac surgery.
Methods: We retrospectively evaluated 600 patients (mean age 55±16 years; 408 male,
192 female) treated postoperatively with iNO between 1997 and 2002. Patients pre-
sented with acute pulmonary hypertension after heart transplantation HTx (n=164),
CABG (n=115), left ventricular assist device (LVAD) implantation (n=82), lung transplan-
tation (n=54), mitral valve replacement (n=39), pulmonary thromboendarterectomy
(n=26) and other operations (n=62), and were treated with NO inhalation initiated on
weaning from cardiopulmonary bypass. Hemodynamic parameters were measured prior
to iNO, at 1, 2, 6, 12, 24 and 48 hours during iNO therapy and after weaning from iNO.
Rebound pulmonary hypertension was prevented by slow weaning.
Results: Prior to iNO PVR, mean PAP and CO for the whole group were 242±140
dynesxsxcm-5, 28±10 mmHg and 5.1±1.7 L/min resp., with high inotropic support (epi-
nephrine 0.24±0.16 µg/kg/min). At 6 hours after institution of iNO (mean dose 18±13
ppm) PVR and mean PAP decreased (135±113 dynesxsxcm-5 and 26±9 mmHg
(p<0.0001) and CO increased (5.7±1.7 L/min (p<0.0001). Hemodynamics improved fur-
ther within 48 hours and the epinephrine dose was progressively reduced (p<0.0001).
Patients were weaned from iNO within 32±35 hours. Irrespective of the etiology of pulmo-
nary hypertension the pulmonary vasodilating effect of iNO was proportional to the mean
PAP prior to therapy, whereas the resultant increase in CO was dependent on the extent
of RV dysfunction. Hemodynamic improvement was more pronounced after LVAD
implantation and HTx than after other operations.
Conclusion: In patients presenting with acute pulmonary hypertension after cardiac sur-
gery iNO selectively reduced right ventricular afterload, thereby effectively improving car-
diac output. Beneficial hemodynamic effects of iNO were dependent on the degree of RV
dysfunction and more pronounced after LVAD implantation and HTx.
3:15 p.m.
851-6 Diffusion Weighted Magnetic Resonance Imaging and 
Neurocognitive Outcomes in Atherosclerotic Patients 
Undergoing Off-Pump Coronary Artery Bypass Surgery
Ehtasham A. Qureshi, Adnan Siddiqui, Khalid M. Zirvi, Karthik Linganathan, Francis 
Sutter, Bruce Caplan, Andrew J. Curtin, Amid Khan, Naushad Shaikh, Gary Friday, 
James F. Burke, The Lankenau Hospital and Research Institute, Wynnewood, PA
Background: Reports of neuro-cognitive deficits following off-pump coronary artery
bypass surgery (OPCABG) are conflicting.These deficits, thought to be secondary to
brain ischemia, have not been evaluated using diffusion-weighted magnetic resonance
imaging (DW-MRI), a sensitive method to detect new ischemic lesions.
Methods: Neurocognitive outcomes were assessed in 17 random patients, mean age 70
± 16 (88% males) undergoing OPCABG. Brain DW-MRI was performed before and after
OPCABG in all patients and evaluated for new ischemic lesions by a neuroradiologist
blinded to the clinical data. All patients were assessed and scored for neuropsychological
impairment by the consensus of two independent neurologists using the standard
National Institute of Health Stroke Scale (NIHSS) and a battery of neurocognitive tests
both before and after the surgery.
Results: New focal lesions were seen in 6 (33%) patients, 4 of these were also found to
have neurocognitive decline as assessed by neuropsychological testing. The clinical and
procedural characteristics were similar in patients with and without new DW-MRI
changes. There was no evidence of definitive clinical stroke, as defined by the NIHSS, in
any patient. No patient had pre-operative atrial fibrillation and 4 (23%) developed atrial
fibrillation after OPCABG; none of these patients had any new ischemic lesions on DW-
MRI.
Conclusions: This study suggests that in patients undergoing OPCABG, ischemic brain
lesions occur frequently and factors other than cardiopulmonary bypass maybe impli-
cated for these findings. Further studies with larger number of patients are needed to
determine the clinical significance, predictors and long-term outcome of brain ischemia
following OPCABG.
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1162-135 Intravenous Wafarin Sodium for Anticoagulation After 
Valve Replacement Surgery
Jerome B. Riebman, Thomas Wentzein, Catherine Weirshauser, Michael Nathanson, 
Santa Clara Valley Medical Center, San Jose, CA
BACKGROUND – After valve surgery, oral wafarin sodium (WS) anticoagulation therapy
is delayed due to postoperative coagulopathy and impaired oral medication absorption.
We evaluated the impact of combining initial intravenous wafarin (IVW) therapy during the
first 24 hours postoperatively with traditional postoperative oral WS therapy.
METHODS - Adults (n=22, age 53.8±2.9 mean±SEM, 12 males) undergoing mechanical
valve implantation received 1-2 doses of IVW postoperatively and after 24-48 hours were
continued on oral WS. IVW (2.5-5 mg) was given the night of surgery or the following
morning (POD#0). A second dose of IVW (2.5-7.5 mg) was given during the second 24
hrs (POD#1) if the patient still was not tolerating oral intake. Subsequent daily oral WS
was given in the evenings, and titrated to an INR between 2.0-3.0. Patients were followed
until POD#14 or hospital discharge. A sex and age matched cohort of valve patients
(n=22, age 52.7±2.5, 12 males) receiving standard oral WS served as a comparison pop-
ulation.
RESULTS – Both groups were similar in medical history, operative variables, transfusion
requirements, thoracic drainage, and outcomes. The study patients received a total mean
dose of 8mg IVW followed by daily oral WS dosing. Cohort patients started oral WS
POD#1 or after. Patients receiving IVW followed by oral WS reached therapeutic INR in
3.4±0.42 days compared to 4.9±0.28 days for oral WS only patients (P<0.05).
CONCLUSION – Early postoperative IVW was not associated with negative clinical
events. Patients receiving initial IVW then oral WS reached therapeutic INR more quickly
than patients receiving oral WS only. Safe, earlier anticoagulation can be accomplished
with combination therapy, and may translate in to reductions of hospital stay and costs.
1162-136 Durability and Outcomes of Mitral Valve Repair for 
Infective Endocarditis
Yukikatzu Okada, Ko Bando, Hitoshi Kasegawa, Kobe City General Hospital, Kobe, 
Japan, National Cardiovascular Center, Osaka, Japan
Background: Mitral valve (MV) repair over replacement has significant advantages for
patients with infective endocarditis (IE). However, the durability and late outcome of MV
repair for IE remains to be determined. We sought to determine the risks for mortality,
